

February 14, 2025

**THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR  
DISSEMINATION IN THE UNITED STATES**

# Izotropic Closes Non-Brokered Private Placement

**VANCOUVER and SACRAMENTO, February 14, 2025, Izotropic Corporation** (CSE: **IZO**) (OTCQB: **IZOZF**) (FSE: **1R3**) ("**Izotropic**" or the "**Company**"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its February 7<sup>th</sup> announcement it has completed a non-brokered private placement financing (the "**Offering**"), whereby the Company issued 3,033,333 units (each, a "**Unit**") at a price of \$0.15 per Unit for gross proceeds of \$455,000.

Each Unit consists of one common share and one transferable warrant (each, a "**Warrant**"), and each Warrant entitles the holder to purchase one additional share at a price of \$0.30 per share for a period of two (2) years from closing of the Offering.

This financing includes two strategic investors the Company expects to be working with in the future.

The use of proceeds from the Offering will be used for general and administrative purposes.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

Completion of this Offering is subject to a number of conditions, including, without limitation, receipt of all necessary regulatory approvals.

None of the securities issued in the Offering will be registered under the *United States Securities Act of 1933*, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

## **About Izotropic:**

More information about Izotropic Corporation can be found on its website at [izocorp.com](http://izocorp.com) and by reviewing its profile on SEDAR at [sedarplus.ca](http://sedarplus.ca).

**Forward-Looking Statements:**

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

**Contacts:**

Robert Thast  
Interim Chief Executive Officer  
Telephone: 1-604-220-5031 or 1-800-IZOCORP ext. 3  
Email: [bthast@izocorp.com](mailto:bthast@izocorp.com)

General Inquiries  
Telephone: 1-604-825-4778 or 1-800-IZOCORP ext. 1  
Email: [info@izocorp.com](mailto:info@izocorp.com)